The individual (single patient) IND for inborn errors of metabolism

Patricia I. Dickson; Jakub Tolar

doi:10.1016/j.ymgme.2014.10.003

The individual (single patient) IND for inborn errors of metabolism

Patricia I. Dickson, Jakub Tolar

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

Under the United States Food and Drug Administration's Expanded Access program, a physician may treat a single patient with an experimental medication under an individual investigational new drug application (iIND). Metabolic geneticists may be among the specialists most likely to be asked to obtain an iIND, because there are many experimental treatments for inborn errors ofmetabolismwhich work in animals but suffer delays in translation to the bedside. The iIND has the potential to help bridge that gap, by gathering initial evidence in support of the use of an experimental drug in humans. If donewith experimental rigor, the datawill be useful, despite being limited to a single patient. However, iINDsmay pose risks to drug development if patients are not carefully selected. Whatever their advantages and disadvantages, iIND studies are here to stay. Metabolic specialists should cautiously consider the iIND as a tremendous opportunity for therapeutic experimentation.

Original language	English (US)
Pages (from-to)	1-3
Number of pages	3
Journal	Molecular Genetics and Metabolism
Volume	116
Issue number	1-2
DOIs	https://doi.org/10.1016/j.ymgme.2014.10.003
State	Published - Sep 1 2015

Bibliographical note

Funding Information:
Supported in part by NIH / NINDS R01NS085381 to P.I.D. and NIH / NCATS (UCLA CTSI) UL1TR000124 . J.T. is supported in part by grants from the National Institutes of Health ( R01 AR063070 and R01AR059947 ), US Department of Defense ( W81XWH-12-1-0609 ), Epidermolysis Bullosa Research Fund , Jackson Gabriel Silver Foundation , and DebRA .

Funding Information:
The iIND is not designed for research, and phase I clinical trials are the standard in any drug development program. The National Institutes of Health and the Food and Drug Administration offer several funding mechanisms, including NeuroNEXT, Rare Disease Clinical Research Networks, and the Orphan Products Development grant program. These programs support clinical trials for novel therapies in patients with inborn errors of metabolism. Additional funding mechanisms for small clinical trials, including n = 1 studies for extremely rare diseases or patient-tailored therapeutics, are needed in order to bring the latest therapeutic options to patients.

Publisher Copyright:
© 2014 Elsevier Inc..

Access

10.1016/j.ymgme.2014.10.003

OpenUrl availability

Full text

Cite this

@article{26135074efac4419b116f4afb71ae415,

title = "The individual (single patient) IND for inborn errors of metabolism",

abstract = "Under the United States Food and Drug Administration's Expanded Access program, a physician may treat a single patient with an experimental medication under an individual investigational new drug application (iIND). Metabolic geneticists may be among the specialists most likely to be asked to obtain an iIND, because there are many experimental treatments for inborn errors ofmetabolismwhich work in animals but suffer delays in translation to the bedside. The iIND has the potential to help bridge that gap, by gathering initial evidence in support of the use of an experimental drug in humans. If donewith experimental rigor, the datawill be useful, despite being limited to a single patient. However, iINDsmay pose risks to drug development if patients are not carefully selected. Whatever their advantages and disadvantages, iIND studies are here to stay. Metabolic specialists should cautiously consider the iIND as a tremendous opportunity for therapeutic experimentation.",

author = "Dickson, {Patricia I.} and Jakub Tolar",

note = "Funding Information: Supported in part by NIH / NINDS R01NS085381 to P.I.D. and NIH / NCATS (UCLA CTSI) UL1TR000124 . J.T. is supported in part by grants from the National Institutes of Health ( R01 AR063070 and R01AR059947 ), US Department of Defense ( W81XWH-12-1-0609 ), Epidermolysis Bullosa Research Fund , Jackson Gabriel Silver Foundation , and DebRA . Funding Information: The iIND is not designed for research, and phase I clinical trials are the standard in any drug development program. The National Institutes of Health and the Food and Drug Administration offer several funding mechanisms, including NeuroNEXT, Rare Disease Clinical Research Networks, and the Orphan Products Development grant program. These programs support clinical trials for novel therapies in patients with inborn errors of metabolism. Additional funding mechanisms for small clinical trials, including n = 1 studies for extremely rare diseases or patient-tailored therapeutics, are needed in order to bring the latest therapeutic options to patients. Publisher Copyright: {\textcopyright} 2014 Elsevier Inc..",

year = "2015",

month = sep,

day = "1",

doi = "10.1016/j.ymgme.2014.10.003",

language = "English (US)",

volume = "116",

pages = "1--3",

journal = "Molecular Genetics and Metabolism",

issn = "1096-7192",

publisher = "Academic Press Inc.",

number = "1-2",

}

TY - JOUR

T1 - The individual (single patient) IND for inborn errors of metabolism

AU - Dickson, Patricia I.

AU - Tolar, Jakub

N1 - Funding Information: Supported in part by NIH / NINDS R01NS085381 to P.I.D. and NIH / NCATS (UCLA CTSI) UL1TR000124 . J.T. is supported in part by grants from the National Institutes of Health ( R01 AR063070 and R01AR059947 ), US Department of Defense ( W81XWH-12-1-0609 ), Epidermolysis Bullosa Research Fund , Jackson Gabriel Silver Foundation , and DebRA . Funding Information: The iIND is not designed for research, and phase I clinical trials are the standard in any drug development program. The National Institutes of Health and the Food and Drug Administration offer several funding mechanisms, including NeuroNEXT, Rare Disease Clinical Research Networks, and the Orphan Products Development grant program. These programs support clinical trials for novel therapies in patients with inborn errors of metabolism. Additional funding mechanisms for small clinical trials, including n = 1 studies for extremely rare diseases or patient-tailored therapeutics, are needed in order to bring the latest therapeutic options to patients. Publisher Copyright: © 2014 Elsevier Inc..

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Under the United States Food and Drug Administration's Expanded Access program, a physician may treat a single patient with an experimental medication under an individual investigational new drug application (iIND). Metabolic geneticists may be among the specialists most likely to be asked to obtain an iIND, because there are many experimental treatments for inborn errors ofmetabolismwhich work in animals but suffer delays in translation to the bedside. The iIND has the potential to help bridge that gap, by gathering initial evidence in support of the use of an experimental drug in humans. If donewith experimental rigor, the datawill be useful, despite being limited to a single patient. However, iINDsmay pose risks to drug development if patients are not carefully selected. Whatever their advantages and disadvantages, iIND studies are here to stay. Metabolic specialists should cautiously consider the iIND as a tremendous opportunity for therapeutic experimentation.

AB - Under the United States Food and Drug Administration's Expanded Access program, a physician may treat a single patient with an experimental medication under an individual investigational new drug application (iIND). Metabolic geneticists may be among the specialists most likely to be asked to obtain an iIND, because there are many experimental treatments for inborn errors ofmetabolismwhich work in animals but suffer delays in translation to the bedside. The iIND has the potential to help bridge that gap, by gathering initial evidence in support of the use of an experimental drug in humans. If donewith experimental rigor, the datawill be useful, despite being limited to a single patient. However, iINDsmay pose risks to drug development if patients are not carefully selected. Whatever their advantages and disadvantages, iIND studies are here to stay. Metabolic specialists should cautiously consider the iIND as a tremendous opportunity for therapeutic experimentation.

UR - http://www.scopus.com/inward/record.url?scp=84940888519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940888519&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2014.10.003

DO - 10.1016/j.ymgme.2014.10.003

M3 - Comment/debate

C2 - 25456747

AN - SCOPUS:84940888519

SN - 1096-7192

VL - 116

SP - 1

EP - 3

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

IS - 1-2

ER -

The individual (single patient) IND for inborn errors of metabolism

Abstract

Bibliographical note

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this